EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis

Colin W Howden, Philip Katz iD, Kenneth R DeVault, David C Metz, David Tamene, Neila Smith, Barbara Hunt, Yu-Ming Chang, Stuart J Spechler

Alimentary Pharmacology & Therapeutics · 2025-03 · 61 (5) · 835-851

DOI: 10.1111/apt.18458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 25.12.2024. Verfasst von Colin W Howden und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Tennessee College of Medicine, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Sulfonamides, Pyrroles, Proton Pump Inhibitors, Gastroesophageal Reflux. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Phathom Pharmaceuticals Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with erosive oesophagitis, and those with persistent symptomatic non‐erosive gastro‐oesophageal reflux disease, require long‐term maintenance treatment with acid‐suppressing agents.

Aim

To evaluate the safety of vonoprazan, a potassium‐competitive acid blocker, in an integrated analysis of data from clinical trials in adults.

Methods

We included 14 clinical trials of vonoprazan conducted in multiple countries. Mean duration of exposure in person‐years to vonoprazan ( n = 5318) was 2068, to comparators lansoprazole ( n = 1925) or esomeprazole ( n = 86) was 751, and to placebo ( n = 779) was 59. We report adverse events, serum gastrin, and liver enzyme levels as the main outcomes. Post‐marketing safety data from December 26, 2014 (date of commercialisation in Japan) to December 25, 2023, are also provided.

Results

Nasopharyngitis was the only adverse event reported by at least 5.0% of patients (6.94% vonoprazan, 5.07% proton pump inhibitor (PPI), 4.49% placebo). Incidence rates per 100 person‐years for serious adverse events were 10.39 for vonoprazan, 10.65 for PPIs, and 1.69 for placebo. One patient each on vonoprazan and lansoprazole was diagnosed with gastric cancer. Mean serum gastrin levels were higher on vonoprazan than lansoprazole but normalised by 4 weeks after discontinuation. Elevated liver enzyme levels were infrequent and of low magnitude with no differences between vonoprazan and PPIs. There were four deaths; none was considered related to study drug.

Conclusions

Vonoprazan was well tolerated. Its safety profile from both clinical trial and post‐marketing data were consistent and comparable to that of its PPI comparators with respect to treatment‐emergent adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesPyrrolesProton Pump InhibitorsGastroesophageal RefluxEsophagitis, PepticEsophagitisHumansMaleFemaleMiddle AgedAdultLansoprazoleAgedEsomeprazoleTreatment OutcomeNasopharyngitis

Stichwörter der Autor:innen

erosive oesophagitisgastro‐oesophageal reflux diseasepotassium‐competitive acid blockervonoprazan

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineSulfonamidesPyrrolesProton Pump InhibitorsLansoprazoleEsomeprazole

Autor:innen und Institutionen

  • University of Tennessee College of Medicine, Memphis, Tennessee, USA.
  • Division of Gastroenterology & Hepatology, Weill Cornell Medicine, New York, New York, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
  • Division of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
  • Phathom Pharmaceuticals, Florham Park, New Jersey, USA.

ORCID-Profile: Philip Katz

Förderung

  • Phathom Pharmaceuticals Inc.

Zitieren

APA

Howden, C. W., Katz, P., DeVault, K. R., Metz, D. C., Tamene, D., Smith, N., Hunt, B., Chang, Y. M., & Spechler, S. J. (2025). Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics, 61(5), 835-851. https://doi.org/10.1111/apt.18458

Vancouver

Howden CW, Katz P, DeVault KR, Metz DC, Tamene D, Smith N, et al. Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis. Alimentary Pharmacology & Therapeutics. 2025;61(5):835-851. doi:10.1111/apt.18458

BibTeX
@article{Howden2025,
  author = {Howden, Colin W and Katz, Philip and DeVault, Kenneth R and Metz, David C and Tamene, David and Smith, Neila and Hunt, Barbara and Chang, Yu-Ming and Spechler, Stuart J},
  title = {Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {5},
  pages = {835--851},
  doi = {10.1111/apt.18458}
}
Kostenlos starten →